NASDAQ •
Healthcare •
Biotechnology •
Quote as of 06/18/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization173.2 mln
Float94.02 mln
Earnings Date07/30/2026
Piotroski F-Score
1
/ 9
Very weak
Beneish M-Score
-3.09
Reliable
Relative Strength
28
/ 100
Underperforming
Debt / Equity
3.33
Highly leveraged
ROE
-237
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
Alector is a US-based clinical-stage biotech company focused on developing treatments that slow or stop diseases that cause the brain to deteriorate over time. Its portfolio includes several drug candidates targeting Alzheimer's, Parkinson's, and related conditions, spanning both clinical and early research stages. The company works alongside GlaxoSmithKline to advance a shared set of treatments aimed at restoring key proteins involved in brain health. Founded in 2013 and based in South San Francisco, Alector continues to build on its science-driven approach to fighting neurological disease.
